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Introduction: We describe the long-term effectiveness and tolerability of intravitreal vascular endothelial growth
factor inhibitor ranibizumab in a patient with pseudoxanthoma elasticum with bilateral macular choroidal
neovascularization secondary to angioid streaks.
Case presentation: A 54-year-old Caucasian man with history of heart disease presented with visual loss in his right
eye. An examination revealed choroidal neovascularization and reduced visual acuity, while no abnormalities were
seen in his left eye. He was diagnosed with angioid streaks associated with pseudoxanthoma elasticum. Off-label
treatment with intravitreal bevacizumab once a month initiated in December 2007 was discontinued after 3 months
due to lack of efficacy. In September 2008, the patient reported reduced visual acuity in his left eye and an examination
revealed changes. Left eye treatment was initiated in October 2008 with a loading dose (three consecutive monthly
intravitreal injections of ranibizumab 0.5mg/50μL) followed by 0.5mg/50μL followed by treatment as needed until May
2014. After 21 ranibizumab injections, an examination revealed angioid streaks and choroidal neovascularization in both
eyes. His right eye showed retinal layer deterioration with outer limiting membrane and photoreceptor inner/outer
segment junction involvement. His left eye had a smaller foveal scar, with other areas preserved. Visual acuity was
stable in his treated left eye, but had deteriorated in his right eye. Ranibizumab treatment was well tolerated with
no adverse events reported.
Conclusions: In the present case, an as-needed regimen of ranibizumab after an initial loading dose, achieved
maintenance of visual function and was well tolerated over a period of almost 6 years in a patient with pseudoxanthoma
elasticum and high cardiovascular risk. As anti-vascular endothelial growth factor agents are associated with increased risk
of systemic effects, particularly arterial thromboembolic events, following intravenous administration, the absence of
serious thromboembolic or cardiovascular adverse events throughout the 6-year treatment period is particularly
encouraging considering our patient’s high cardiovascular risk status.
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Pseudoxanthoma elasticum (PXE) is a rare, inherited disease
with typical ocular manifestations including angioid streaks
(seen as breaks in the Bruch’s membrane) [1,2]. A common
and serious complication of angioid streaks is the develop-
ment of macular choroidal neovascularization (CNV), which
can result in significant and irreversible impairment of vision
[3]. The introduction of intravitreally administered agents
that inhibit vascular endothelial growth factor (VEGF) has
improved outcomes in patients with CNV [3]. Ranibizumab
– a recombinant humanized anti-VEGF-A monoclonal anti-
body antigen-binding fragment – is approved for intravitreal
use for neovascular (wet) age-related macular degeneration
and visual impairment due to diabetic macular edema,
macular edema secondary to retinal vein occlusion or to
CNV secondary to pathologic myopia [4]. Evidence suggests
that anti-VEGF agents are effective in patients with angioid
streak-related CNV associated with PXE [5-8].
We describe the long-term effectiveness and tolerability of
the off-label use of anti-VEGF-A agent ranibizumab, in a pa-
tient with PXE with bilateral CNVsecondary to angioid streaks.
Case presentation
A 54-year-old Caucasian man with hypertension, diabetes
mellitus, peripheral vascular insufficiency, and a history of
ischemic heart disease, presented in December 2007 withFigure 1 Fundus photography and optical coherence tomography scans in
(A, A’) Fundus autofluorescence, (B, B’) fluorescein angiography, (C, C’) optical c
images are before ranibizumab treatment. The right eye images are after three in
images (A-A’) show the macular involvement by the choroidal neovascularizatio
(gray arrowhead). The choroidal neovascularization is visible in both eyes by fluor
tomography shows retinal pigment epithelium detachment in the right eye with
epithelium interruption, intraretinal fluid and neuroretinal detachment are observsignificant visual loss in his right eye (RE) and the occur-
rence of metamorphopsia and central scotoma. His left
eye (LE) was unaffected. He was in treatment with low-
dose aspirin and oral antihyperglycemics and antihyper-
tensives, and had undergone two triple coronary bypasses
in the previous years (latest in 2004). His heart disease
and diabetes were well compensated; his blood pressure
and hemodynamic parameters were controlled.
Eye examinations (fundus photography, autofluores-
cence; fluorescein angiography; and optical coherence
tomography, OCT) revealed the presence of CNV in his
RE, while no abnormalities were seen in his LE. Best
corrected visual acuity (BCVA) was 20 Early Treatment
Diabetic Retinopathy Study (ETDRS) letters for his RE
and 78 ETDRS letters for his LE. He was diagnosed with
angioid streaks associated with PXE, which was confirmed
by skin biopsy. Off-label treatment of his RE with intravit-
real injection of bevacizumab (1.25mg/50μL) once a
month was initiated in December 2007, but discontinued
after 3 months in February 2008 due to lack of efficacy
(no improvement in visual acuity).
In September 2008, He reported reduced visual acuity in
his LE. Eye examinations (fundus photography, fluorescent
angiography and OCT) revealed changes in his LE and
confirmed angioid streaks and CNV in his RE (Figure 1).
Photodynamic therapy was proposed but a second opinionthe left eye (pre-ranibizumab) and the right eye (post-bevacizumab).
oherence tomography; (A, B, C) right eye; (A’, B’, C’) left eye. The left eye
travitreal bevacizumab injections (September 2008). The color fundus
n (white arrowheads) mainly in the right eye with severe bleeding
escein angiography (white arrows in B and B’). The optical coherence
subretinal fluid over the neovascularization (C). Initial retinal pigment
able in the left eye (C’).
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the anti-VEGF agent ranibizumab (unavailable in Italy at
that time) was proposed and initiated in October 2008 with
a loading dose (three consecutive monthly intravitreal
injections of ranibizumab 0.5mg/50μL) followed by
treatments as needed until May 2014 (endpoint of the
present observation). His RE was not treated after
February 2008.
Eye examinations – fundus photography, fluorescein
angiography, B-scan OCT and en face OCT – were per-
formed in May 2014. The reason for using en face OCT
was to better investigate the “cystic-like appearance” of
outer retinal tubulation (ORT) that may be confused with
cystoid macular edema related to leakage from CNV.
According to other authors [9], the presence of ORT
during follow-up supports the concept that these struc-
tures are not a sign of ongoing neovascular activity and its
presence, if not identified as ORT, can potentially lead to
unnecessary treatment.Figure 2 Fundus photography (autofluorescence) and optical coherenc
Left eye received intravitreal ranibizumab injections (loading dose during first
autofluorescence, (B, B’) fluorescein angiography, (C, C’) B-scan OCT; (D, D’) E
and choroidal neovascularization were visible in both eyes, while full posterior
In RE the extension of the scar was observable in en face scan (D) (black
the subfoveal region with external limiting membrane (ELM) and inner/o
observable over the lesion with no signs of inflammation. The B-scan and
tabulation (ORT) along the posterior pole lesion (black arrows) that are geFrom October 2008 to May 2014, 21 intravitreal injec-
tions of ranibizumab were given in his LE: two in 2008,
four in 2009 (one of which was part of the loading dose),
three in 2010, four in 2011, four in 2012, three in 2013,
and one in May 2014.
An eye examination in May 2014 revealed angioid
streaks and CNV in both eyes (Figure 2). In his RE, a large
fibrotic lesion was localized in the mainly posterior pole,
while in his LE, the fovea was involved. His RE showed
retinal layer deterioration with outer limiting membrane
(OLM) and photoreceptor inner/outer segment junction
involvement, while in his LE, the smaller foveal scar
preserved the photoreceptor junction, the OLM and the
retinal layers (Figure 2).
His visual acuity was stable in his ranibizumab-treated
LE but had further decreased in his RE. Intraocular pres-
sure was normal (16mmHg) in both eyes. Ranibizumab
treatment was well tolerated with no adverse events
reported throughout the 6-year treatment period.e tomography (OCT) images after almost 6 years of follow-up.
three months, followed by treatment PRN) (May 2014). (A, A’) fundus
n face OCT; (A, B, C, D) right eye; (A’, B’, C’, D’) left eye. Angioid streaks
pole retinal involvement was observable only in the right eye (A, B, C, D).
arrowhead). The LE B-scan OCT shows the neovascularization scar in
uter photoreceptor junction preservation. The neuroretinal layers are
the en face OCT images (C’, D’) show the presence of outer retinal
nerally observed in chronic disease with retinal rearrangement.
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In our patient, early intravitreal ranibizumab administra-
tion to his less severely affected LE preserved moderate
visual function over the entire observation period,
whereas in his first affected RE, bevacizumab had failed
to preserve visual function. This may be explained by
the fact that the CNV in his RE was in an advanced
stage, already associated with irreversible vision impair-
ment. Published evidence suggests that to achieve optimal
results in the management of CNV in PXE, anti-VEGF
therapy should be started as early as possible [6]. In a case
report of 5-year ranibizumab in PXE, a 51-year-old patient
achieved complete disease stabilization with 12 intravitreal
injections in the first year [10]. During the subsequent 4
years, he received two additional injections for mild recur-
rence only and his LE vision remained stable over the entire
observation period.
Our patient was treated with a different regimen of rani-
bizumab loading dose for 3 months and then as needed,
with a mean interval between injections of 3.5 months, so
our findings demonstrate the effectiveness of a regimen
with longer between-dose intervals. These observations
support those from two case series of PXE treated with
ranibizumab: >85% of patients had improved or stable
BCVA [7,8]. Notably, in our patient, during the last 3
years, injection frequency has decreased progressively to
only one during the first 5 months of 2014 given as a pre-
cautionary measure.
The absence of serious thromboembolic or cardiovascu-
lar (CV) events throughout the 6-year treatment period is
noteworthy considering the high CV risk of our patient.
Systemic effects, particularly arterial thromboembolic
events, following intravenous anti-VEGF agents, have
raised concern regarding the use of these agents in
patients with PXE due to the high CV risk. Ranibizumab
with its shorter systemic half-life versus other anti-VEGF
agents may have safety advantages in this population
[11-14].
Finally, our case also highlights the benefits of en face
OCT [15], which allowed for transversal assessment of
photoreceptor involvement and outer retinal tubulation
of the outer nuclear retinal layers (Figures 2D and 2D’).
Conclusions
In conclusion, in a patient with PXE and high CV risk, a
6-year ‘as-needed’ regimen of ranibizumab (after an initial
loading dose) achieved maintenance of visual function
and was well tolerated. As anti-VEGF agents are associ-
ated with increased risk of systemic effects, particularly
arterial thromboembolic events, following intravenous
administration, the absence of serious thromboembolic or
CV adverse events throughout the 6-year treatment period
is particularly encouraging considering the high CV risk
status of this patient.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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